JP2009533021A5 - - Google Patents

Download PDF

Info

Publication number
JP2009533021A5
JP2009533021A5 JP2009502214A JP2009502214A JP2009533021A5 JP 2009533021 A5 JP2009533021 A5 JP 2009533021A5 JP 2009502214 A JP2009502214 A JP 2009502214A JP 2009502214 A JP2009502214 A JP 2009502214A JP 2009533021 A5 JP2009533021 A5 JP 2009533021A5
Authority
JP
Japan
Prior art keywords
seq
antibody
nucleotide sequence
sequence selected
substantial homology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009502214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009533021A (ja
JP5165672B2 (ja
Filing date
Publication date
Priority claimed from GB0606276A external-priority patent/GB0606276D0/en
Priority claimed from GB0607376A external-priority patent/GB0607376D0/en
Application filed filed Critical
Priority claimed from PCT/GB2007/001139 external-priority patent/WO2007110648A1/en
Publication of JP2009533021A publication Critical patent/JP2009533021A/ja
Publication of JP2009533021A5 publication Critical patent/JP2009533021A5/ja
Application granted granted Critical
Publication of JP5165672B2 publication Critical patent/JP5165672B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009502214A 2006-03-29 2007-03-29 Tshrに対するアゴニスト抗体 Active JP5165672B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0606276.4 2006-03-29
GB0606276A GB0606276D0 (en) 2006-03-29 2006-03-29 Antibodies
GB0607376A GB0607376D0 (en) 2006-04-12 2006-04-12 Antibodies
GB0607376.1 2006-04-12
PCT/GB2007/001139 WO2007110648A1 (en) 2006-03-29 2007-03-29 Agonist antibodies against tshr

Publications (3)

Publication Number Publication Date
JP2009533021A JP2009533021A (ja) 2009-09-17
JP2009533021A5 true JP2009533021A5 (https=) 2010-05-13
JP5165672B2 JP5165672B2 (ja) 2013-03-21

Family

ID=38093407

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009502214A Active JP5165672B2 (ja) 2006-03-29 2007-03-29 Tshrに対するアゴニスト抗体

Country Status (5)

Country Link
US (1) US8603466B2 (https=)
EP (1) EP1999153B1 (https=)
JP (1) JP5165672B2 (https=)
ES (1) ES2482145T3 (https=)
WO (1) WO2007110648A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5784504B2 (ja) * 2008-12-24 2015-09-24 アールエスアール リミテッド ヒト抗tshr抗体
US8785603B2 (en) 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
FI3380620T3 (fi) 2015-11-23 2024-08-01 Novartis Ag Optimoituja lentiviruksen siirtovektoreita ja niiden käyttötapoja
RU2018127657A (ru) 2015-12-30 2020-01-31 Новартис Аг Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
ES2912408T3 (es) 2017-01-26 2022-05-25 Novartis Ag Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
CN110582509A (zh) 2017-01-31 2019-12-17 诺华股份有限公司 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
RU2020116579A (ru) 2017-10-25 2021-11-25 Новартис Аг Способы получения клеток, экспрессирующих химерный антигенный рецептор
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113490528B (zh) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
US20220227875A1 (en) * 2019-05-31 2022-07-21 University Of Florida Research Foundation, Incorporated Vector-based therapy for thyroid disease
BR112022011902A2 (pt) 2019-12-20 2022-09-06 Novartis Ag Terapias de combinação
JP2023529211A (ja) 2020-06-11 2023-07-07 ノバルティス アーゲー Zbtb32阻害剤及びその使用
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
JP7819176B2 (ja) 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022229853A1 (en) 2021-04-27 2022-11-03 Novartis Ag Viral vector production system
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
EP4538290A1 (en) * 2022-06-10 2025-04-16 MediMabbio Inc. Fusion protein comprising antibody binding specifically to tigit and interleukin-15, and use thereof
AU2023369684A1 (en) 2022-10-26 2025-04-17 Novartis Ag Lentiviral formulations
PE20252789A1 (es) 2023-05-24 2025-12-22 Kumquat Biosciences Inc Compuestos heterociclicos y usos de estos
CN118994398A (zh) * 2024-09-27 2024-11-22 兰州大学第二医院 一种抗促甲状腺激素受体单克隆抗体7c3及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0796280B1 (en) * 1994-12-28 2003-03-26 University Of Kentucky Murine monoclonal anti-idiotype antibody 3h1
US20020098190A1 (en) * 1997-06-13 2002-07-25 Malaya Chatterjee Compositions and methods for treating tumors bearing HMFG and CEA antigens
EP1196534A1 (en) * 1999-07-01 2002-04-17 The Procter & Gamble Company Transparent or translucent, liquid or gel type automatic dishwashing detergent product
ES2736165T3 (es) * 2001-08-23 2019-12-26 Rsr Ltd Regiones epítopo de un receptor de tirotropina (TSH), sus usos y anticuerpos para las mismas

Similar Documents

Publication Publication Date Title
JP2009533021A5 (https=)
RU2009126766A (ru) Антитела человека к дельта-подобному лиганду-4 человека
JP5972871B2 (ja) 抗il−23ヘテロ二量体特異的抗体
JP7173964B2 (ja) 抗p53抗体
JP2009502171A5 (https=)
JP2010511388A5 (https=)
RU2013107776A (ru) Антитело к противоопухолевому антигену и способы применения
CN104144944A (zh) 抗-脂阿拉伯甘露聚糖抗体和使用该抗体对抗酸杆菌感染的免疫测定
FI3309176T3 (fi) Immunoglobuliinin yksittäinen vaihteleva domeeni -vasta-aineita ox40l:ää vastaan, konstrukteja ja niiden terapeuttinen käyttö
JP2013520174A5 (https=)
JP2012501670A5 (https=)
JP2020530285A5 (https=)
RU2010132647A (ru) Анти-mif антитела
JP2019506155A5 (https=)
JP2012523848A5 (https=)
IL273196B2 (en) Claudin6 antibodies and methods of treating cancer
HRP20140502T1 (hr) Humanizirana anti-cxcr4 antitijela za lijeäśenje karcinoma
CN106604932A (zh) 人白细胞介素‑2的免疫刺激单克隆抗体
WO2019137397A1 (zh) Pd-l1抗体、其抗原结合片段及医药用途
RU2017107773A (ru) Антитела, специфичные к ммр9
JP2022527151A5 (https=)
CN108178799B (zh) 一种抗ca125糖类抗原的纳米抗体及其应用
RU2009120536A (ru) Рекомбинантные антитела против васкулярного эндотелиального фактора роста (vegf)
CN114853888A (zh) 抗tslp纳米抗体及其应用
CN106749667A (zh) 一种抗癌胚抗原的纳米抗体及其应用